Omnipred

Inflammation, Conjunctivitis, Conjunctivitis + 4 more

Treatment

4 FDA approvals

20 Active Studies for Omnipred

What is Omnipred

Prednisolone acetate

The Generic name of this drug

Treatment Summary

Prednisolone acetate is a steroid medication that is used to control inflammation. It was approved by the FDA in 1955 and is sometimes known under the brand name Ocu-Pred.

Blephamide

is the brand name

Omnipred Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Blephamide

Prednisolone acetate

1961

39

Approved as Treatment by the FDA

Prednisolone acetate, also known as Blephamide, is approved by the FDA for 4 uses including Inflammation and Organ Transplantation .

Inflammation

Organ Transplantation

Inflammation

Inflammatory Conditions

Helps manage Inflammatory Conditions

Effectiveness

How Omnipred Affects Patients

Prednisolone acetate works by blocking certain signals in the body that cause inflammation. Its effects only last for a few hours, but patients may take multiple doses of this drug. Taking this drug can interfere with the normal activity of the hormones that control inflammation, which may make people more prone to infections. Patients should be aware of this potential side effect.

How Omnipred works in the body

Corticosteroids decrease inflammation by reducing blood vessel enlargement and preventing white blood cells from travelling to the site of inflammation. When they bind to the glucocorticoid receptor, they cause changes in genes which have downstream effects over time. These changes include stopping neutrophil cell death, reducing the production of inflammatory compounds, and increasing anti-inflammatory molecules like interleukin-10. Low doses of corticosteroids reduce inflammation, while higher doses have an immunosuppressive effect. When taken for a long time, corticosteroids also bind to a different receptor, which causes an increase in sodium and a decrease

When to interrupt dosage

The measure of Omnipred is subject to the diagnosed state, including Ocular Infections, Irritations and Inflammations, Ocular Inflammation and Inflammatory Conditions. The quantity of dosage deviates, in line with the approach of delivery (e.g. Ophthalmic or Solution / drops - Ophthalmic) featured in the table beneath.

Condition

Dosage

Administration

Conjunctivitis

0.002 mg/mg, , 10.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.2 mg/mL, 0.2 %, 1.0 %, 0.12 %, 0.006 mg/mg, 0.5 %, 1.25 mg/mL, 1.0 mg/mL, 10.0 mg/mg, 1.25 mg, 5.0 mg/mL, 16.7 mg/mL, 0.005 mg/mg

, Ointment, Ophthalmic, Ointment - Ophthalmic, Oral, Suspension, Suspension - Oral, Suspension / drops, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Solution / drops - Ophthalmic, Solution / drops, Ointment - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Kit, Solution, Kit - Ophthalmic

Conjunctivitis

0.002 mg/mg, , 10.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.2 mg/mL, 0.2 %, 1.0 %, 0.12 %, 0.006 mg/mg, 0.5 %, 1.25 mg/mL, 1.0 mg/mL, 10.0 mg/mg, 1.25 mg, 5.0 mg/mL, 16.7 mg/mL, 0.005 mg/mg

, Ointment, Ophthalmic, Ointment - Ophthalmic, Oral, Suspension, Suspension - Oral, Suspension / drops, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Solution / drops - Ophthalmic, Solution / drops, Ointment - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Kit, Solution, Kit - Ophthalmic

Ocular Infections, Irritations and Inflammations

0.002 mg/mg, , 10.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.2 mg/mL, 0.2 %, 1.0 %, 0.12 %, 0.006 mg/mg, 0.5 %, 1.25 mg/mL, 1.0 mg/mL, 10.0 mg/mg, 1.25 mg, 5.0 mg/mL, 16.7 mg/mL, 0.005 mg/mg

, Ointment, Ophthalmic, Ointment - Ophthalmic, Oral, Suspension, Suspension - Oral, Suspension / drops, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Solution / drops - Ophthalmic, Solution / drops, Ointment - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Kit, Solution, Kit - Ophthalmic

Organ Transplantation

0.002 mg/mg, , 10.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.2 mg/mL, 0.2 %, 1.0 %, 0.12 %, 0.006 mg/mg, 0.5 %, 1.25 mg/mL, 1.0 mg/mL, 10.0 mg/mg, 1.25 mg, 5.0 mg/mL, 16.7 mg/mL, 0.005 mg/mg

, Ointment, Ophthalmic, Ointment - Ophthalmic, Oral, Suspension, Suspension - Oral, Suspension / drops, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Solution / drops - Ophthalmic, Solution / drops, Ointment - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Kit, Solution, Kit - Ophthalmic

Eye Infections, Bacterial

0.002 mg/mg, , 10.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.2 mg/mL, 0.2 %, 1.0 %, 0.12 %, 0.006 mg/mg, 0.5 %, 1.25 mg/mL, 1.0 mg/mL, 10.0 mg/mg, 1.25 mg, 5.0 mg/mL, 16.7 mg/mL, 0.005 mg/mg

, Ointment, Ophthalmic, Ointment - Ophthalmic, Oral, Suspension, Suspension - Oral, Suspension / drops, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Solution / drops - Ophthalmic, Solution / drops, Ointment - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Kit, Solution, Kit - Ophthalmic

Inflammation

0.002 mg/mg, , 10.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.2 mg/mL, 0.2 %, 1.0 %, 0.12 %, 0.006 mg/mg, 0.5 %, 1.25 mg/mL, 1.0 mg/mL, 10.0 mg/mg, 1.25 mg, 5.0 mg/mL, 16.7 mg/mL, 0.005 mg/mg

, Ointment, Ophthalmic, Ointment - Ophthalmic, Oral, Suspension, Suspension - Oral, Suspension / drops, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Solution / drops - Ophthalmic, Solution / drops, Ointment - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Kit, Solution, Kit - Ophthalmic

Inflammatory Conditions

0.002 mg/mg, , 10.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.2 mg/mL, 0.2 %, 1.0 %, 0.12 %, 0.006 mg/mg, 0.5 %, 1.25 mg/mL, 1.0 mg/mL, 10.0 mg/mg, 1.25 mg, 5.0 mg/mL, 16.7 mg/mL, 0.005 mg/mg

, Ointment, Ophthalmic, Ointment - Ophthalmic, Oral, Suspension, Suspension - Oral, Suspension / drops, Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Solution / drops - Ophthalmic, Solution / drops, Ointment - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Kit, Solution, Kit - Ophthalmic

Warnings

Omnipred has one cautions and should not be taken when encountering the conditions listed in the table below.

Omnipred Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Prednisolone Acetate may interact with Pulse Frequency

There are 20 known major drug interactions with Omnipred.

Common Omnipred Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Prednisolone acetate.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be increased when combined with Prednisolone acetate.

Alectinib

Major

The metabolism of Alectinib can be increased when combined with Prednisolone acetate.

Alpelisib

Major

The metabolism of Alpelisib can be increased when combined with Prednisolone acetate.

Aminophylline

Major

The metabolism of Aminophylline can be increased when combined with Prednisolone acetate.

Omnipred Toxicity & Overdose Risk

Prednisolone acetate is toxic in large doses, with the lowest dose that causes death in mice being 1680mg/kg. Those who overdose on oral prednisolone acetate may experience more severe side effects associated with corticosteroids. Treatment for an overdose includes emptying the stomach through vomiting or lavage, as well as reducing the dose or treating patients every other day. An overdose through the eyes is not expected to cause any problems.

image of a doctor in a lab doing drug, clinical research

Omnipred Novel Uses: Which Conditions Have a Clinical Trial Featuring Omnipred?

189 active investigations are being conducted to assess the potential benefits of Omnipred in ameliorating Inflammation, Inflammatory Conditions and superficial ocular infections.

Condition

Clinical Trials

Trial Phases

Inflammation

59 Actively Recruiting

Phase 2, Not Applicable, Phase 1, Early Phase 1, Phase 3

Conjunctivitis

0 Actively Recruiting

Eye Infections, Bacterial

0 Actively Recruiting

Ocular Infections, Irritations and Inflammations

0 Actively Recruiting

Conjunctivitis

0 Actively Recruiting

Organ Transplantation

0 Actively Recruiting

Inflammatory Conditions

1 Actively Recruiting

Phase 2

Omnipred Reviews: What are patients saying about Omnipred?

3

Patient Review

8/15/2010

Omnipred for Severe Inflammation of the Eye

I had cataract surgery two days ago and my doctor prescribed Omnipred. The problem is that every time I use it, the burning sensation is unbearable (like pouring lemon juice on a paper cut). Is this normal? How long will it last?

1.7

Patient Review

10/23/2008

Omnipred for Inflammation of the Eye

1.3

Patient Review

6/26/2010

Omnipred for Inflammation of the Eye Following Surgery

I used this a few days before surgery and for a couple weeks after to prevent infection. It seemed effective, but I noticed a side effect of weight gain that was difficult to lose. Has anyone else experienced this?

Patient Q&A Section about omnipred

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Omnipred a prescription?

"An Authorized Generic version of Omnipred has been approved by the FDA. An Authorized Generic is a prescription drug that is produced by a brand company under a New Drug Application (NDA) and marketed as a generic under a private label."

Answered by AI

What is prednisolone tablets prescribed for?

"Prednisolone is a medicine used to treat a wide range of health problems. It helps by reducing swelling (inflammation) and can also calm down your immune system."

Answered by AI

What is Omnipred eye drops used for?

"Prednisolone is a medication used to treat certain eye conditions caused by inflammation or injury. Prednisolone works by relieving symptoms such as swelling, redness, and itching. It belongs to a class of drugs called corticosteroids."

Answered by AI

Is Omnipred a steroid?

"Omnipred is a steroid that is used to treat inflammation caused by allergies, eye infections, or any other irritation to the eye."

Answered by AI

Clinical Trials for Omnipred

Image of University of Oklahoma Health Campus in Oklahoma City, United States.

Disulfiram for Rheumatoid Arthritis

18 - 75
All Sexes
Oklahoma City, OK

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent joint inflammation and systemic immune activation. Obesity is common among individuals with RA and is associated with increased disease activity, reduced treatment response, and worse functional outcomes. Inflammation in adipose tissue, driven in part by activation of the NLRP3 inflammasome and downstream gasdermin D (GSDMD)-mediated pathways, may contribute to systemic inflammation and RA disease severity. Disulfiram (DSF), an FDA-approved medication for alcohol use disorder, has recently been identified as an inhibitor of GSDMD-mediated inflammatory signaling and pyroptosis. Preclinical studies suggest that DSF reduces inflammasome activation, inflammatory cytokine release, and metabolic dysfunction. This study is a 12-week, randomized, double-blind, placebo-controlled pilot trial designed to evaluate the safety, tolerability, and preliminary efficacy of DSF in overweight and obese adults with active RA despite stable disease-modifying antirheumatic drug (DMARD) therapy. Participants will be randomized to receive either DSF (250 mg daily) or placebo. The primary objective is to assess safety and tolerability. Secondary and exploratory objectives include evaluating the effects of DSF on systemic inflammation, RA disease activity, metabolic parameters, and adipose tissue inflammasome activation. Findings from this study will inform the feasibility and design of larger clinical trials targeting GSDMD-mediated inflammation in RA.

Phase 2
Waitlist Available

University of Oklahoma Health Campus

Beatriz Y Hanaoka, MD, MSc

Image of University of California, Riverside in Riverside, United States.

Acetazolamide for Altitude Sickness

18 - 65
All Sexes
Riverside, CA

High altitude travel can lead to inflammation in the body and activation of innate immune cells. The investigators' prior research demonstrates that 1 to 3 days at 3800 m elevation leads to increased expression of genes in blood cells that code for proteins that signal cell damage (damage associated molecular patterns (DAMPs)), cell receptors involved in innate immune responses, as well as increases in monocyte and neutrophil cells which promote inflammation. This study will investigate the potential mechanisms underlying these effects using the drug Acetazolamide, a carbonic anhydrase inhibitor which is known to reduce symptoms of Acute Mountain Sickness.

Phase < 1
Waitlist Available

University of California, Riverside

Have you considered Omnipred clinical trials?

We made a collection of clinical trials featuring Omnipred, we think they might fit your search criteria.
Go to Trials
Image of Exercise and Performance Nutrition Laboratory in Saint Charles, United States.

Multi-Strain Postbiotic for Inflammation and Gastrointestinal Symptoms

18 - 55
All Sexes
Saint Charles, MO

This study will evaluate the effects of a multi-strain postbiotic supplement on markers of inflammation, immune function, gastrointestinal symptoms, psychological well-being, and intestinal permeability in healthy adults. The primary objective is to determine whether four weeks of postbiotic supplementation alters physiological and perceptual responses to a standardized bout of moderate-to-high intensity exercise compared with placebo. Approximately 50 healthy men and women aged 18 to 55 years will be enrolled in a randomized, double-blind, placebo-controlled, parallel-group clinical trial. Participants will be randomly assigned to receive either a multi-strain postbiotic supplement or a matched placebo for 28 days. At the end of the supplementation period, participants will complete a 45-minute treadmill exercise bout at 75% of their individually determined maximum heart rate. Blood samples will be collected to assess biomarkers of inflammation, immune activity, and recovery. Gastrointestinal symptoms, intestinal permeability, anxiety, and perceived recovery will be evaluated using validated questionnaires. This study is designed to determine whether postbiotic supplementation modulates physiological stress responses and subjective well-being following prolonged exercise in healthy adults.

Waitlist Available
Paid Trial

Exercise and Performance Nutrition Laboratory

Chad M Kerksick, PhD

Image of ATX Hyperbarics in Austin, United States.

Hyperbaric Oxygen Therapy for Cardiovascular Fitness

30 - 60
All Sexes
Austin, TX

The purpose of this study is to determine whether hyperbaric oxygen therapy (HBOT) at 1.75 atmospheres of pressure (ATA) improves cardiovascular fitness (VO₂ max) and reduces inflammation in healthy adults. HBOT involves breathing pure oxygen in a pressurized chamber and is considered investigational for this use. Recent research has shown that different HBOT pressures can have different effects on inflammation. Specifically, some inflammatory cytokines (measurable markers of inflammation in the body) appear to decrease at low pressures like 1.3 ATA, while a different set of cytokines responds better at higher pressures, such as 2.0 ATA. Cytokines are small proteins that play a crucial role in cell signaling, particularly within the immune system. They help regulate inflammation, infection response, and overall immune function. While some cytokines promote inflammation to fight off threats, others help reduce inflammation when it's no longer needed. An imbalance in cytokines - especially excessive inflammatory cytokines - can contribute to chronic inflammation, cardiovascular disease, and other health issues. In this study, we are testing an intermediate pressure - 1.75 ATA - to see if we can target both sets of cytokines at once. If successful, this approach could offer broader anti-inflammatory benefits. We are also interested in how this intermediate pressure may improve VO₂ max, a key indicator of cardiovascular fitness. Since VO₂ max is strongly linked to heart health and overall longevity, finding a safe and effective way to improve it has meaningful implications not just for athletes, but for anyone looking to enhance their fitness and well-being.

Recruiting
Has No Placebo

ATX Hyperbarics (+1 Sites)

Image of University of New Brunswick in Fredericton, Canada.

Mediterranean Diet for Toddler Health

24 - 36
All Sexes
Fredericton, Canada

Toddlerhood (ages 2-3) is a critical window when the gut microbiome is still developing and eating habits are being established. Yet, many Canadian toddlers eat diets high in sugar and salt, which may affect long-term health. This study will test whether a MED diet can improve dietary inflammation, gut health, and body composition in toddlers and whether a tailored nutrition education program for parents can help families maintain healthy eating patterns. In this study, toddlers will be randomly assigned to a 3-week MED diet or their usual diet. Families in the MED diet group will receive free meal boxes for the 3 weeks, plus guidance from a nutrition researcher through a structured education program. The standard diet group will continue their regular diet with general nutrition advice. Researchers will collect dietary information, body composition assessments, and stool samples to measure gut microbiome composition and metabolites. This first study of a controlled diet intervention in toddlers, combining behavioral support, high-quality food provision, and advanced gut microbiome analysis, will help understand how early diet shapes lifelong eating habits and health, guiding public health strategies and precision nutrition approaches to prevent chronic disease from early life.

Waitlist Available
Has No Placebo

University of New Brunswick

Dr. Maryam Kebbe, PhD, CLC

Have you considered Omnipred clinical trials?

We made a collection of clinical trials featuring Omnipred, we think they might fit your search criteria.
Go to Trials
Image of UConn Health in Farmington, United States.

Cognitive Remediation for Memory and Thinking Difficulties

18+
All Sexes
Farmington, CT

The goal of this clinical trial is to determine if a neuroscience-based computerized cognitive remediation ("brain training") program can treat neurocognitive dysfunction (i.e., memory or thinking difficulties) that emerges in some older adults following a viral infection. The main questions it aims to answer are: * Does computerized cognitive remediation improve cognitive performance and day-to-day functioning in older adults with postviral neurocognitive dysfunction? * Will treatment effects be maintained over time, leading to better long term cognitive outcomes? * Does the treatment lead to reductions in blood-based markers of inflammation as a potential mechanism of cognitive symptom improvement? * Can the treatment be optimized and refined based on feedback from participants to improve user (patient) experience? Researchers will compare the computerized cognitive remediation program to an active computer-based control condition (alternative computer activities) to see if the computerized cognitive remediation program works to treat postviral neurocognitive dysfunction. Participation takes approximately 43-48 hours over 7 months, with most activities (40-46 hours) completed within the first 7-8 weeks, including: * Initial intake visit: Eligibility confirmation (\~2-3 hours) * Computer activities: About 5 hours per week for \~6 weeks (total \~30 hours) completed on a computer tablet provided by the study and loaned to participants for use during the treatment phase * Weekly remote check-in meetings: \~30 minutes each during treatment * Blood draws: Two sessions (before and after treatment), \~20-30 minutes each * Three research visits: Pre-treatment, post-treatment, and 6-month follow-up (\~2-3 hours each, including assessments of cognitive, emotional, and daily functioning)

Recruiting
Has No Placebo

UConn Health

Cutter Lindbergh, Ph.D.

Image of Department of Nutritional Sciences in Storrs, United States.

Freeze-dried Grape Powder for Healthy Aging

50 - 75
All Sexes
Storrs, CT

The purpose of this study is to investigate the effects of consuming grape powder on immune profiles in healthy middle- and older-aged individuals. Specifically, the investigators are interested in evaluating the potential effects of grapes in influencing markers of immune function, inflammation, and metabolism that are known to change with aging. Grapes contain several nutrients and antioxidant polyphenols such as resveratrol, quercetin, vitamin K and fiber, which are known to promote heart and immune health. However, the effects of grapes on altering immune profiles within the context of aging is not well understood. Therefore, this study will explore how daily grape consumption impacts certain markers of immunity in healthy middle- and older-aged adults. The main study procedures include consumption of a freeze-dried grape powder and control powder (which tastes the same but has none of the grape compounds that are being studied) mixed with water as a beverage on a daily basis for 4 weeks each. The investigators will additionally ask that participants avoid eating grapes and certain other antioxidant/grape-related foods and beverages throughout the 13-week study. Participants will additionally be asked to complete surveys about their diet, physical activity, and medical history, as well as provide blood samples and body weight measures throughout the course of the study. Participation in the study is expected to last about 6.25 hours over the course of 13 weeks and will include 7 visits.

Recruiting
Paid Trial

Department of Nutritional Sciences

Image of Abcentra Investigational Site in Los Angeles, United States.

Orticumab for Heart Attack

18+
All Sexes
Los Angeles, CA

The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is: Clinical effects of orticumab treatment on inflammation of the coronary artery parameters measured with CCTA Researchers will compare the effects with placebo group after 6 months of treatment Participants will Keep the planned study visit appointments Provide complete information about medical and medical history Speak to the study doctor before changing any of non-study treatments, including starting new medications, receiving any vaccinations, or setting out to join any other clinical studies

Phase 2
Recruiting

Abcentra Investigational Site (+6 Sites)

Abcentra

Have you considered Omnipred clinical trials?

We made a collection of clinical trials featuring Omnipred, we think they might fit your search criteria.
Go to Trials